阿瑞匹坦口服与静脉及福沙匹坦静脉预防腹腔镜袖状胃切除术后恶心呕吐的比较:回顾性队列研究
该回顾性队列研究比较阿瑞匹坦80 mg口服、阿瑞匹坦32.4 mg静脉及福沙匹坦75 mg静脉预防腹腔镜袖状胃切除术后恶心呕吐(PONV)的效果。结果显示三组在术后即刻(PACU+1 h)PONV无差异,但福沙匹坦在PACU+12 h、PACU+24 h及总给药次数上优于其他两组,且住院时间更短。
要点
- 福沙匹坦75 mg静脉在术后12小时、24小时及总给药次数上优于阿瑞匹坦口服和静脉组。
- 三组在术后即刻(PACU+1 h)PONV无差异,饮食订单时间和疼痛控制也无差异。
- 福沙匹坦75 mg静脉组住院时间更短。
核心结论
- 在该回顾性队列中,福沙匹坦75 mg静脉总体优于阿瑞匹坦32.4 mg静脉和80 mg口服。
研究设计与样本
- 回顾性队列研究,比较阿瑞匹坦80 mg口服、阿瑞匹坦32.4 mg静脉和福沙匹坦75 mg静脉三组。
主要发现
- 术后即刻(PACU+1 h)三组PONV无差异。
- 福沙匹坦在PACU+12 h、PACU+24 h及住院期间总给药次数上显著优于其他两组。
- 三组饮食订单时间和疼痛控制无差异,福沙匹坦组住院时间更短。
临床怎么用
- 对于腹腔镜袖状胃切除术患者,可优先考虑福沙匹坦75 mg静脉预防PONV以缩短住院时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The most common postoperative (post-op) complication in bariatric surgery is postoperative nausea and vomiting (PONV) with up to 70% of patients reporting symptoms. PONV is also associated with longer post-anesthesia care unit (PACU) time and hospital stays overall. Aprepitant has shown efficacy in reducing PONV and has been added to many standard antiemetic regimens; however, the bioavailability of the oral formulation is not ideal in bariatric surgery patients, and the ideal dose intravenously (IV) has not been established. METHODS: This retrospective cohort study compared aprepitant 80 mg orally (PO) to aprepitant 32.4 mg intravenous (IV) and fosaprepitant 75 mg IV. The presence of PONV was defined by the number of doses of antiemetics administered postoperatively within four windows: PACU plus 1 h, defined as time upon entry to PACU+1 h, PACU + 12 h, PACU + 24 h, and any further doses administered while admitted thereafter. Secondary outcomes included time to diet ordered, length of hospital stay, and pain control. RESULTS: There was no difference in PONV between aprepitant 80 mg PO vs. 32.4 mg IV vs. fosaprepitant 75 mg in the immediate interim after surgery (PACU + 1 h); however, fosaprepitant was statistically superior to the other two groups at PACU + 12 h, PACU + 24 h, and total doses administered throughout admission. There was no difference in time to diet ordered or pain control, but fosaprepitant was superior when looking at length of stay. CONCLUSION: In this retrospective cohort, fosaprepitant 75 mg IV was found to be superior overall to aprepitant 32.4 mg IV and 80 mg PO.
引用
- Dahman M, Ratermann C, Stuart F, et al. Comparison of aprepitant 80 mg oral, aprepitant 32.4 mg intravenous, and fosaprepitant 75 mg intravenous in the prevention of postoperative nausea and vomiting in patients undergoing laparoscopic sleeve gastrectomy, a retrospective cohort study. Surg Endosc. 2026. PMID: 42754628. doi:10.1007/s00464-026-13367-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。